UCSF

Thomas Kearney, PharmD

Associate Dean and Professor
Department of Clinical Pharmacy
Kearney
[email protected]
Phone: +1 415 502-2882
Fax: +1 415 502-6012
513 Parnassus Avenue, Rm 124
UCSF Box 0403
San Francisco, CA 94143
United States

Links

UCSF Profiles

Educational programs

UCSF centers, institutes, and research programs

Managing Director, San Francisco Division, California Poison Control System (CPCS)

External affiliations

Associate Editor, Poisoning and Drug Overdose

What I do

As associate dean of academic affairs, I represent the dean’s office and provide guidance, assessment, and action on all issues related to policies and procedures for academic affairs. The primary duties cover the following that concern faculty within the School of Pharmacy: appointment and advancement; compensation and benefits; problem resolution; adherence to UC system-wide and campus policy and procedures; and liaison to the UCSF vice-provost office of academic affairs.

As the managing director of the SF Division of the California Poison Control System, I have administrative responsibilities for professional services provided by the poison center hotline (hiring, training, evaluation, and QA for pharmacy staff) and implementation (at the SF site). I also serve as the attending for hospital consultations one day per week with oversight of APPE students and medical toxicology fellows.

Departmental research area

clinical research

My research expertise

clinical toxicology, antidotes for poisoning, pharmacoepidemiology, poison center operations

Clinical expertise

clinical toxicology

Degrees

PharmD, University of California, San Francisco, 1980

Biography

Associate Dean of Academic Affairs and Professor of Clinical Pharmacy at the School of Pharmacy, University of California, San Francisco; Clinical Toxicology Consultant for the San Francisco Division of the California Poison Control System, and completed a one-year mid-career fellowship (Institute for Health Policy Studies, Institute for Health and Aging and Health Research Training Program, UCSF School of Medicine) in health services research. Dr. Kearney is a graduate of the University of California San Francisco School of Pharmacy. He completed a Residency in Hospital Pharmacy at the University of Michigan and a two-year post-doctoral fellowship in clinical toxicology at University of California, San Diego and San Francisco. He has served as Associate Director of the Louisiana State Regional Poison Control Center and the Executive Director of the Delaware Valley Regional Poison Center at Children's Hospital of Philadelphia. He has served in leadership positions in the American Association of Poison Control Centers (Treasurer) and is a Diplomate and past-President of the Board of the American Board of Applied Toxicology. He has served as the Associate Editor for the publication: Poisoning and Drug Overdose - a Lange clinical manual, Appleton and Lange publishers.

Research keywords

pharmacoepidemiology, antidotes for poisoning, poison center operations, clinical toxicology, Hemofiltration, Carbamazepine, Physostigmine, Postmortem Changes, Serotonin Syndrome, Cyproheptadine, poisoning, Drug-Related Side Effects and Adverse Reactions, antidotes, Poison Control Centers, Drug Overdose, Transdermal Patch, Tramadol, Serotonin Antagonists, Cholinergic Antagonists

Licensure and certifications

Licentiate in Pharmacy, California, 1980
Diplomate, American Board of Applied Toxicology, 1991 -

Publications

Clinard VB, Kearney TE, Repplinger DJ, Smollin CG, Youmans SL. An interprofessional clinical toxicology advanced pharmacy practice experience. Curr Pharm Teach Learn. 2019 05; 11(5):505-512.
Arens AM, Kearney T. Adverse Effects of Physostigmine. J Med Toxicol. 2019 Jul; 15(3):184-191.
Nguyen H, Pan A, Smollin C, Cantrell LF, Kearney T. An 11-year retrospective review of cyproheptadine use in serotonin syndrome cases reported to the California Poison Control System. J Clin Pharm Ther. 2019 Apr; 44(2):327-334.
Arlow RL, Paddock LE, Niu X, Kirstein L, Haffty BG, Goyal S, Kearney T, Toppmeyer D, Stroup AM, Khan AJ. Breast-conservation Therapy After Neoadjuvant Chemotherapy Does Not Compromise 10-Year Breast Cancer-specific Mortality. Am J Clin Oncol. 2018 12; 41(12):1246-1251.
Arens AM, Shah K, Al-Abri S, Olson KR, Kearney T. Safety and effectiveness of physostigmine: a 10-year retrospective review<sup/>. Clin Toxicol (Phila). 2018 02; 56(2):101-107.
Smollin CG, Petrie MS, Kearney T. Carbamazepine and carbamazepine-10,11-epoxide clearance measurements during continuous venovenous hemofiltration in a massive overdose. Clin Toxicol (Phila). 2016 Jun; 54(5):424-7.
Tsutaoka BT, Ho RY, Fung SM, Kearney TE. Comparative Toxicity of Tapentadol and Tramadol Utilizing Data Reported to the National Poison Data System. Ann Pharmacother. 2015 Dec; 49(12):1311-6.
Wu AH, Hamilton R, Middleberg R, Kacinko S, Kearney T. Investigation of postmortem absorption and redistribution after the application of a fentanyl patch. J Forensic Sci. 2015 Mar; 60(2):532-5.
Al-Abri SA, Woodburn C, Olson KR, Kearney TE. Ventricular dysrhythmias associated with poisoning and drug overdose: a 10-year review of statewide poison control center data from California. Am J Cardiovasc Drugs. 2015 Feb; 15(1):43-50.
Kearney T, Hiatt P, Birdsall E, Smollin C. Pepper spray injury severity: ten-year case experience of a poison control system. Prehosp Emerg Care. 2014 Jul-Sep; 18(3):381-6.
Armenian P, Kearney TE. Pediatric ergot alkaloid exposures reported to the California Poison Control System: 1997-2008. Clin Toxicol (Phila). 2014 Mar; 52(3):214-9.
Lung DD, Kearney TE, Brasiel JA, Olson KR. Predictors of Death and Prolonged Renal Insufficiency in Ethylene Glycol Poisoning. J Intensive Care Med. 2015 Jul; 30(5):270-7.
Al-Abri SA, Kearney T. Baking soda misuse as a home remedy: case experience of the California Poison Control System. J Clin Pharm Ther. 2014 Feb; 39(1):73-7.
Kearney TE, Lieu D, Singer N, Tsutaoka B, Ho R, Olson K. Investigating the reliability of substance toxicity information found on the Internet in pediatric poisonings. Pediatr Emerg Care. 2013 Dec; 29(12):1249-54.
Wu AH, Kearney T. Lack of impairment due to confirmed codeine use prior to a motor vehicle accident: role of pharmacogenomics. J Forensic Leg Med. 2013 Nov; 20(8):1024-7.
Thundiyil JG, Rowley F, Papa L, Olson KR, Kearney TE. Risk factors for complications of drug-induced seizures. J Med Toxicol. 2011 Mar; 7(1):16-23.
Kim-Katz SY, Anderson IB, Kearney TE, MacDougall C, Hudmon KS, Blanc PD. Topical antacid therapy for capsaicin-induced dermal pain: a poison center telephone-directed study. Am J Emerg Med. 2010 Jun; 28(5):596-602.
Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Ann Pharmacother. 2010 Jun; 44(6):1022-9.
Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. J Clin Psychiatry. 2009 Jan; 70(1):122-9.
Haller C, Kearney T, Bent S, Ko R, Benowitz N, Olson K. Dietary supplement adverse events: report of a one-year poison center surveillance project. J Med Toxicol. 2008 Jun; 4(2):84-92.
Kearney TE, Hiatt PH, Olson KR. Alternative models for telephone response to pediatric poisonings. Prehosp Emerg Care. 2007 Jul-Sep; 11(3):284-92.
Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. J Med Toxicol. 2007 Mar; 3(1):15-9.
Kearney TE, Van Bebber SL, Hiatt PH, Olson KR. Protocols for pediatric poisonings from nontoxic substances: are they valid? Pediatr Emerg Care. 2006 Apr; 22(4):215-21.
Make a gift
We see a time when precise therapeutics—used safely and effectively—improve the health of people everywhere.
© 2002–2020 The Regents of the University of California